Published in Clin Cancer Res on October 01, 2007
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature (2008) 2.51
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012) 1.23
The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene (2009) 1.19
Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis (2012) 1.13
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat (2012) 1.10
Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem (2009) 1.08
Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci U S A (2013) 1.05
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol (2012) 1.04
Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat (2008) 1.03
Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol (2010) 0.99
MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol (2013) 0.95
Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer. Proc Natl Acad Sci U S A (2014) 0.91
Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol (2010) 0.84
Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305. Mol Cancer Res (2012) 0.83
The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer. PLoS One (2013) 0.82
MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy. Mol Med (2012) 0.81
RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Res (2013) 0.81
Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. Oncotarget (2016) 0.79
Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells. Endocrinology (2012) 0.77
Relation between outcomes and expression of estrogen receptor-α phosphorylated at Ser(167) in endometrioid endometrial cancer. Cancer Sci (2014) 0.77
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells. J Steroid Biochem Mol Biol (2015) 0.77
Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer (2012) 0.76
The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. Drug Des Devel Ther (2015) 0.76
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. Pharmacogenomics J (2014) 0.75
Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery. Recent Pat Anticancer Drug Discov (2016) 0.75
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 4.80
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem (2003) 3.41
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature (2008) 2.51
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A (2009) 2.29
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther (2008) 2.18
SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther (2010) 2.15
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res (2006) 2.13
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther (2005) 2.02
Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol (2009) 1.99
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res (2005) 1.99
Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.97
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer (2012) 1.97
FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res (2010) 1.95
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem (2003) 1.95
Psychosocial interventions following self-harm: systematic review of their efficacy in preventing suicide. Br J Psychiatry (2007) 1.93
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol (2011) 1.93
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem (2006) 1.68
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res (2011) 1.64
T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. J Biol Chem (2003) 1.62
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene (2002) 1.62
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther (2009) 1.56
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol (2006) 1.49
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulators. Biochem Soc Trans (2008) 1.43
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res (2005) 1.42
People admitted to hospital with physical disability have increased length of stay: implications for diagnosis related group re-imbursement in England. Age Ageing (2007) 1.41
Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene (2003) 1.39
Imaging breast cancer morphology using probe-based confocal laser endomicroscopy: towards a real-time intraoperative imaging tool for cavity scanning. Breast Cancer Res Treat (2015) 1.39
A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst (2013) 1.36
LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat (2011) 1.33
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (2011) 1.32
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol (2011) 1.31
Neuro-cognitive performance in children with type 1 diabetes--a meta-analysis. J Pediatr Psychol (2008) 1.27
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer (2009) 1.27
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res (2004) 1.26
Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope (2009) 1.23
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol (2002) 1.23
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther (2007) 1.21
miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res (2013) 1.21
Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer (2006) 1.18
Renal tumourigenesis in male rats in response to chronic dietary ochratoxin A. Food Addit Contam (2005) 1.18
Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer (2005) 1.17
Fluorescence lifetime imaging of unstained tissues: early results in human breast cancer. J Pathol (2003) 1.15
Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol (2008) 1.15
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol (2011) 1.14
The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity. Carcinogenesis (2004) 1.13
Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis (2005) 1.13
A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat (2011) 1.12
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer (2005) 1.11
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res (2006) 1.10
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer (2008) 1.10
Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proc Natl Acad Sci U S A (2012) 1.09
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem (2004) 1.09
Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One (2013) 1.08
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08
The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer (2006) 1.07
SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis (2013) 1.04
ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res (2006) 1.02
Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies. Heart (2006) 1.02
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat (2010) 1.01
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat (2010) 1.01
T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif. Nucleic Acids Res (2005) 1.01
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res (2011) 1.00
Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation. Philos Trans R Soc Lond B Biol Sci (2014) 0.98
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res (2009) 0.98
Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med (2011) 0.98